clinical trial · NCT05504837
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
Cystic FibrosisKB407 (Nebulization)
brief summary
This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
started
Jun 30, 2023
primary completion
Dec 1, 2025
completion
Jan 1, 2026
last updated
Aug 21, 2025
official title
KB407-02 A Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of Cystic Fibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol